Company intelligence / Profile preview
Darnatein
- Ownership
- Private
- Development stage
- Other
Overview
Darnatein is a South Korean biotechnology company focused on developing next-generation regenerative biologics for musculoskeletal and tissue repair. As a subsidiary of OSR Holdings, the company utilizes its proprietary Design-Augmented (DA) Biologics platform, which integrates synthetic biology and AI-enhanced protein engineering to create super-agonists that restore signaling balance in the body. Its lead candidate, DRT-101, is a chimeric BMP-7/Activin protein being developed as a disease-modifying osteoarthritis drug (DMOAD). The company's pipeline also includes DRT-102, a BMP-2 super-agonist currently in clinical development for spinal fusion applications.
- Therapeutic areas
- RheumatologyOther
- Modalities
- Recombinant proteinRecombinant fusion proteinBiologic
- Industry
- Biotech
Drug pipeline
3 assets2 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Darnatein.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Darnatein.